These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 35051615)
1. Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells. Chaturvedi P; George V; Shrestha N; Wang M; Dee MJ; Zhu X; Liu B; Egan J; D'Eramo F; Spanoudis C; Gallo V; Echeverri C; You L; Kong L; Fang B; Jeng EK; Rhode PR; Wong HC Mol Ther; 2022 Mar; 30(3):1171-1187. PubMed ID: 35051615 [TBL] [Abstract][Full Text] [Related]
2. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8 Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice. Shrestha N; Chaturvedi P; Zhu X; Dee MJ; George V; Janney C; Egan JO; Liu B; Foster M; Marsala L; Wong P; Cubitt CC; Foltz JA; Tran J; Schappe T; Hsiao K; Leclerc GM; You L; Echeverri C; Spanoudis C; Carvalho A; Kanakaraj L; Gilkes C; Encalada N; Kong L; Wang M; Fang B; Wang Z; Jiao JA; Muniz GJ; Jeng EK; Valdivieso N; Li L; Deth R; Berrien-Elliott MM; Fehniger TA; Rhode PR; Wong HC Aging Cell; 2023 May; 22(5):e13806. PubMed ID: 36967480 [TBL] [Abstract][Full Text] [Related]
4. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Luo Y; Liu H; Fu H; Ding GS; Teng F Front Immunol; 2022; 13():974377. PubMed ID: 36458010 [TBL] [Abstract][Full Text] [Related]
5. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215 [TBL] [Abstract][Full Text] [Related]
6. IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma. Homann L; Rentschler M; Brenner E; Böhm K; Röcken M; Wieder T Cells; 2022 Apr; 11(9):. PubMed ID: 35563820 [TBL] [Abstract][Full Text] [Related]
7. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617 [TBL] [Abstract][Full Text] [Related]
8. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259 [TBL] [Abstract][Full Text] [Related]
9. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer. Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560 [No Abstract] [Full Text] [Related]
11. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878 [TBL] [Abstract][Full Text] [Related]
14. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030 [TBL] [Abstract][Full Text] [Related]
15. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434 [TBL] [Abstract][Full Text] [Related]
16. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. Xu Q; Long Q; Zhu D; Fu D; Zhang B; Han L; Qian M; Guo J; Xu J; Cao L; Chin YE; Coppé JP; Lam EW; Campisi J; Sun Y Aging Cell; 2019 Dec; 18(6):e13027. PubMed ID: 31493351 [TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer. Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992 [TBL] [Abstract][Full Text] [Related]
18. Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Liu Y; Lomeli I; Kron SJ Cells; 2024 Jul; 13(15):. PubMed ID: 39120312 [TBL] [Abstract][Full Text] [Related]
19. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer. Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]